Calithera Biosciences, Inc. (CALA)
USD 0.01
(4900.0%)
USD 0.01
(4900.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2022 | -23.78 Million USD | 57.9% |
| 2021 | -56.49 Million USD | 43.74% |
| 2020 | -100.42 Million USD | -92.24% |
| 2019 | -52.24 Million USD | -2.32% |
| 2018 | -51.05 Million USD | -5.33% |
| 2017 | -48.47 Million USD | -357.27% |
| 2016 | -10.6 Million USD | -73.64% |
| 2015 | -6.1 Million USD | 94.01% |
| 2014 | -101.96 Million USD | -201.51% |
| 2013 | -33.82 Million USD | -1433.79% |
| 2012 | -2.2 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2022 Q2 | -39.42 Million USD | 6.04% |
| 2022 Q1 | -41.95 Million USD | 25.74% |
| 2022 FY | -23.78 Million USD | 57.9% |
| 2022 Q4 | -23.78 Million USD | 25.78% |
| 2022 Q3 | -32.04 Million USD | 18.71% |
| 2021 Q2 | -88.53 Million USD | 9.29% |
| 2021 Q1 | -97.6 Million USD | 2.81% |
| 2021 Q3 | -81.13 Million USD | 8.36% |
| 2021 Q4 | -56.49 Million USD | 30.36% |
| 2021 FY | -56.49 Million USD | 43.74% |
| 2020 Q3 | -113.42 Million USD | -5.5% |
| 2020 FY | -100.42 Million USD | -92.24% |
| 2020 Q4 | -100.42 Million USD | 11.46% |
| 2020 Q1 | -32.67 Million USD | 37.46% |
| 2020 Q2 | -107.51 Million USD | -229.05% |
| 2019 Q4 | -52.24 Million USD | -299.49% |
| 2019 Q1 | -31.27 Million USD | 38.75% |
| 2019 FY | -52.24 Million USD | -2.32% |
| 2019 Q3 | -13.07 Million USD | 80.72% |
| 2019 Q2 | -67.84 Million USD | -116.94% |
| 2018 Q3 | -61.13 Million USD | -9.42% |
| 2018 Q2 | -55.87 Million USD | -1.88% |
| 2018 Q1 | -54.84 Million USD | -13.13% |
| 2018 FY | -51.05 Million USD | -5.33% |
| 2018 Q4 | -51.05 Million USD | 16.48% |
| 2017 FY | -48.47 Million USD | -357.27% |
| 2017 Q3 | -39.41 Million USD | 32.05% |
| 2017 Q2 | -57.99 Million USD | 34.89% |
| 2017 Q1 | -89.07 Million USD | -740.22% |
| 2017 Q4 | -48.47 Million USD | -23.0% |
| 2016 Q4 | -10.6 Million USD | 8.61% |
| 2016 FY | -10.6 Million USD | -73.64% |
| 2016 Q2 | -7.32 Million USD | 39.78% |
| 2016 Q3 | -11.6 Million USD | -58.34% |
| 2016 Q1 | -12.16 Million USD | -99.28% |
| 2015 Q3 | -8.43 Million USD | 25.51% |
| 2015 Q2 | -11.31 Million USD | 84.68% |
| 2015 Q1 | -73.87 Million USD | 27.55% |
| 2015 FY | -6.1 Million USD | 94.01% |
| 2015 Q4 | -6.1 Million USD | 27.59% |
| 2014 Q2 | -27.75 Million USD | 0.0% |
| 2014 Q3 | -34.85 Million USD | -25.59% |
| 2014 FY | -101.96 Million USD | -201.51% |
| 2014 Q4 | -101.96 Million USD | -192.58% |
| 2013 FY | -33.82 Million USD | -1433.79% |
| 2013 Q4 | -33.82 Million USD | 0.0% |
| 2012 FY | -2.2 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| America Great Health | 1.81 Million USD | 1409.659% |
| Ampio Pharmaceuticals, Inc. | -3.81 Million USD | -523.46% |
| Aridis Pharmaceuticals, Inc. | 1.25 Million USD | 1996.73% |
| Biora Therapeutics, Inc. | 32.21 Million USD | 173.832% |
| Bio-Path Holdings, Inc. | -939 Thousand USD | -2433.014% |
| Better Therapeutics, Inc. | -860 Thousand USD | -2665.698% |
| Comera Life Sciences Holdings, Inc. | 328.44 Thousand USD | 7341.788% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | 4.57 Million USD | 620.46% |
| Eloxx Pharmaceuticals, Inc. | -5.82 Million USD | -308.466% |
| Evelo Biosciences, Inc. | 3.19 Million USD | 843.746% |
| Evolutionary Genomics, Inc. | 3.16 Million USD | 851.102% |
| Finch Therapeutics Group, Inc. | 5 Million USD | 575.51% |
| Galera Therapeutics, Inc. | 134.04 Million USD | 117.744% |
| Innovation1 Biotech Inc. | 179.15 Thousand USD | 13376.584% |
| Kiromic BioPharma, Inc. | 12.33 Million USD | 292.771% |
| Molecular Templates, Inc. | 707 Thousand USD | 3464.215% |
| Navidea Biopharmaceuticals, Inc. | 438.44 Thousand USD | 5524.866% |
| NexImmune, Inc. | -3.13 Million USD | -659.021% |
| Orgenesis Inc. | 21.78 Million USD | 209.186% |
| Panbela Therapeutics, Inc. | 2.61 Million USD | 1009.213% |
| Point of Care Nano-Technology, Inc. | -498.00 USD | -4776004.418% |
| PaxMedica, Inc. Common Stock | -4.71 Million USD | -404.921% |
| Scopus BioPharma Inc. | -124.57 Thousand USD | -18992.916% |
| Sorrento Therapeutics, Inc. | 110.87 Million USD | 121.453% |
| Statera Biopharma, Inc. | 14.41 Million USD | 264.986% |
| TRACON Pharmaceuticals, Inc. | -7.59 Million USD | -213.125% |
| Trevena, Inc. | 2.25 Million USD | 1153.366% |
| Vaxxinity, Inc. | 10.13 Million USD | 334.751% |
| Vaccinex, Inc. | -1.28 Million USD | -1746.661% |
| Vicapsys Life Sciences, Inc. | 344.44 Thousand USD | 7005.291% |
| Viracta Therapeutics, Inc. | 13.23 Million USD | 279.659% |
| ZIVO Bioscience, Inc. | 71.96 Thousand USD | 33152.166% |